Abstract | BACKGROUND: METHODS: We performed a single-center, randomized, open-label study in SAR subjects (n = 100). Participants were randomized to receive BD (256 μg), MNT (10 mg), or hBD (128 μg)+MNT for 14 days. Symptom severity scores, nasal cavity volume (NCV), fraction of exhaled nitric oxide (FeNO), eosinophil cationic protein (ECP), histamine and cysteinyl- leukotrienes (CysLTs), and T-cell subsets were assessed before and after treatment. RESULTS: All treatments significantly improved symptoms from baseline; however, hBD+MNT produced significantly greater improvements in nasal congestion compared with BD or MNT alone. The BD and hBD+MNT groups had fewer patients with uncontrolled symptoms and improved NCV to a greater level than the MNT group. FeNO was decreased to a significantly greater extent from baseline after hBD+MNT treatment than after BD and MNT treatments. ECP, histamine, and CysLTs showed significantly greater decreases after BD and hBD+MNT treatments than after MNT treatment. BD decreased T-helper 1 (Th1) and Th2 cells and increased T-regulatory (Treg) cells in nasal mucosa and MNT decreased Th1 cells and increased Treg cells in peripheral blood, and this trend was reflected with hBD+MNT. CONCLUSION: The hBD+MNT combination may have an overall better efficacy profile than BD and MNT monotherapy for treatment of SAR.
|
Authors | Hui Chen, Hongfei Lou, Yang Wang, Feifei Cao, Luo Zhang, Chengshuo Wang |
Journal | International forum of allergy & rhinology
(Int Forum Allergy Rhinol)
Vol. 8
Issue 11
Pg. 1242-1252
(11 2018)
ISSN: 2042-6984 [Electronic] United States |
PMID | 30144304
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2018 ARS-AAOA, LLC. |
Chemical References |
- Acetates
- Anti-Inflammatory Agents
- Cyclopropanes
- Leukotriene Antagonists
- Quinolines
- Sulfides
- Budesonide
- montelukast
|
Topics |
- Acetates
(therapeutic use)
- Administration, Intranasal
- Adolescent
- Adult
- Anti-Inflammatory Agents
(therapeutic use)
- Budesonide
(therapeutic use)
- Cyclopropanes
- Drug Therapy, Combination
- Female
- Humans
- Leukotriene Antagonists
(therapeutic use)
- Male
- Middle Aged
- Quinolines
(therapeutic use)
- Rhinitis, Allergic, Seasonal
(drug therapy)
- Sulfides
- Treatment Outcome
- Young Adult
|